terms and conditions

Genomenon Completes $1.8 Million Extended Seed Financing Round

November 10th, 2016

ANN ARBOR, Mich., November 10, 2016 – Genomenon Inc., a DNA interpretation software company, today
announced the completion of its Extended Seed financing of $1.8 million. The financing will fuel the completion
and launch of Genomenon’s initial product, Mastermind, a novel analytic and visualization tool for DNA variant
interpretation. Investors included two University of Michigan funds, Michigan Angel Fund and an angel group
formed by Rehmann owners.

 
Mastermind is used for clinical diagnostics and academic research to eliminate the DNA analysis bottleneck in
cancer and genetic disease diagnostics. It reduces the time pathologists and geneticists spend researching
and interpreting genetic variants by automatically mining millions of medical publications to find correlations
between genes, variants required for clinical diagnosis.

 
“The fundamental bottleneck in diagnosing cancer and genetic diseases is the time spent manually
researching DNA mutations” said Mark Kiel MD, Founder and CSO of Genomenon. “We have been able to
dramatically reduce the time pathologists and geneticists spend interpreting genetic mutations by automatically
mining millions of medical publications to find correlations between genes, variants required for clinical
diagnosis.”

 
Genomenon spun out of the University of Michigan in 2015, which enabled it to attract the investments from
two different university funds. MINTS (Michigan Investment in New Technology Start-ups) and the newly
formed Monroe-Brown Fund both invested in the company. Genomenon was Monroe-Brown’s first investment.
The company originally set out to raise $1.0M in new financing and with the strong interest, the investment was
oversubscribed.
“We’re really grateful to the Michigan start-up and investment community” said Mike Klein, CEO of
Genomenon. “It’s a testimony to the eco-system in Michigan that companies like Genomenon can spin great
technology out of the university and find the local funding to launch a successful venture.”
Mastermind, Genomenon’s first product, is a comprehensive knowledge-base built on mining millions of
medical publications that automatically finds correlations between genes, variants and diseases tied to the
primary scientific literature required for clinical diagnosis of cancer and genetic diseases. It is due to launch in
December of 2016.

 
About Genomenon:
Genomenon’s genome interpretation software is used for clinical diagnostics in cancer and genetic diseases.
Genomenon reduces the time Pathologists and Geneticists spend researching and interpreting genetic variants
from hours to minutes. Mastermind, our comprehensive knowledge-base, is built on mining millions of medical
publications that automatically finds correlations between genes, variants and diseases tied to the primary
scientific literature required for clinical diagnosis.

 
For more information, visit www.genomenon.com or email sales@genomenon.com.
Press Contact: Jessica Francis 440.840.4987 or email jessicafrancisPR@gmail.com